BUZZ-Incyte rises after lifting blood cancer drug sales forecast
Shares of drugmaker Incyterise 4.5% to $73.3 premarketINCY raises its annual sales forecast for its blood cancer treatment, Jakafi, to a range between $3 billion and $3.05 billion, from its prior forecast of $2.95 billion to $3 billion Company posts Q2 adjusted profit of $1.57 per share, beating analysts’ estimate of $1.47 per share, according to data compiled by LSEGReports total revenue of $1.22 billion for the quarter, versus estimate of $1.15 billionUp to last close, stock up 1.6% YTD
Shares of drugmaker Incyte (INCY.O) rise 4.5% to $73.3 premarket
INCY raises its annual sales forecast for its blood cancer treatment, Jakafi, to a range between $3 billion and $3.05 billion, from its prior forecast of $2.95 billion to $3 billion Company posts Q2 adjusted profit of $1.57 per share, beating analysts’ estimate of $1.47 per share, according to data compiled by LSEG
Reports total revenue of $1.22 billion for the quarter, versus estimate of $1.15 billion
Up to last close, stock up 1.6% YTD
